Al-dulaimi, S., Thomas, R., Matta, S., & Roberts, T
doi:10.4103/1008-682x.179252
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
Bull WHO 48:1, 1973
Diabetic nephropathy Complications and treatment
The effects on gastric emptying are reported to be reduced with long-term use